Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
AEON Financials AEON Biopharma, Inc.
4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Net income
ROEROA
Equity
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$39M | — | — | 71.3% | -705.4% | -$17M | — | $3M |
| 2024 | — | $42M | — | — | -147.0% | 1336.9% | — | — | $13000 |
| 2022 | — | -$53M | — | — | 18.3% | -487.6% | -$36M | — | $10M |
| 2021 | — | $8M | — | — | -48.4% | 3.0% | — | — | $497412 |
Net income
ROEROA
Equity
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$1M | — | — | 7.5% | -19.5% | — | — | $3M |
| Mar '26 | — | -$12M | — | — | 70.4% | -136.7% | — | — | $6M |
| Dec '25 | — | -$37M | — | — | 67.5% | -667.9% | -$5M | — | $3M |
| Sep '25 | — | -$5M | — | — | 22.8% | -52.0% | -$3M | — | $6M |
| Jun '25 | — | -$7M | — | — | 41.9% | -57.0% | -$2M | — | $8M |
| Mar '25 | — | $9M | — | — | -80.3% | 65.9% | -$8M | — | $10M |
| Dec '24 | — | $2M | — | — | -7.3% | 66.3% | — | — | $13000 |
| Sep '24 | — | -$6M | — | — | 19.2% | -154.1% | — | — | $537000 |
| Jun '24 | — | $164M | — | — | -587.2% | 2862.1% | — | — | $3M |
| Mar '24 | — | -$118M | — | — | 59.5% | -3892.4% | — | — | $2M |
| Dec '23 | — | -$26M | — | — | 17.1% | -383.4% | — | — | $5M |
| Sep '23 | — | -$298M | — | — | 231.9% | -1689.7% | — | — | $16M |
| Jun '23 | — | -$15M | — | — | 134.2% | -70.6% | — | — | — |
| Mar '23 | — | -$18M | — | — | 241.0% | -81.6% | — | — | — |
| Dec '22 | — | -$35M | — | — | 12.0% | -320.7% | -$8M | — | $10M |
| Sep '22 | — | -$10M | — | — | 90.4% | -3.8% | — | — | $27759 |
| Jun '22 | — | $2M | — | — | -15.1% | 0.7% | — | — | $7758 |
| Mar '22 | — | $3M | — | — | -19.6% | 1.0% | — | — | $166243 |
| Dec '21 | — | $247874 | — | — | -1.5% | 0.1% | — | — | $497412 |
| Sep '21 | — | $6M | — | — | -32.9% | 2.0% | — | — | $663540 |
Valuation over time
How the market has priced AEON against its own fundamentals since 2023-07 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
P/E
Frequently asked questions
Is AEON growing its revenue and profit?
See the revenue and net-income charts above for AEON Biopharma, Inc.'s multi-year trend.
How much debt does AEON have?
As of FY2025, AEON Biopharma, Inc. reported — of total debt against $3M of cash.
What is AEON's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is AEON's P/E ratio?
As of Sep '26, AEON Biopharma, Inc. traded at a price-to-earnings ratio of about 1.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.